Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News NEKTAR THERAPEUTICS NKTR

Healthcare

Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that... see more

Add To Watchlist

Recent & Breaking News (NDAQ:NKTR)

Why is Biotech Stock Nektar Therapeutics Surging Higher?

Equities.com June 13, 2014

US FDA ADVISORY COMMITTEE RECOMMENDS NO CARDIOVASCULAR OUTCOMES TRIAL FOR PERIPHERALLY-ACTING MU-OPIOID RECEPTOR ANTAGONIST (PAMORA) CLASS INCLUDING MOVANTIK

PR Newswire June 12, 2014

Nektar Therapeutics Stock Trading Halted Today; FDA Advisory Committee to Discuss Peripherally-Acting Opioid Receptor Antagonists

PR Newswire June 11, 2014

Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, at 50th ASCO Meeting

PR Newswire June 1, 2014

Positive Data from Phase 2 Trial of NKTR-102 in Patients with Avastin®-Refractory High-Grade Glioma Presented at 50th ASCO Meeting

PR Newswire May 31, 2014

Nektar Appoints Ivan Gergel, M.D. as Senior Vice President, Drug Development & Chief Medical Officer

PR Newswire May 19, 2014

Nektar Therapeutics To Present at the UBS 2014 Global Healthcare Conference in New York City

PR Newswire May 16, 2014

Nektar Therapeutics Reports Financial Results for the First Quarter of 2014

PR Newswire May 7, 2014

Nektar to Announce Financial Results for the First Quarter 2014 on Wednesday, May 7, 2014, After Close of U.S.-Based Financial Markets

PR Newswire May 1, 2014

Nektar Reports Positive Preclinical Data for Two Oncology Programs at 2014 AACR

PR Newswire April 9, 2014

Nektar Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results

PR Newswire February 26, 2014

Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2013 on Wednesday, February 26, 2014, After Close of U.S.-Based Financial Markets

PR Newswire February 19, 2014

Five Star Equities Issues New Research Reports on ARIA, CVM, NKTR and NTCT

Accesswire January 27, 2014

Nektar Therapeutics Prices Public Offering of Common Stock

PR Newswire January 22, 2014

Nektar Therapeutics Announces Public Offering of 8,500,000 Shares of Common Stock

PR Newswire January 21, 2014

Nektar Presents Positive Clinical Data from a Phase 1 Study of Etirinotecan Pegol (NKTR-102) in Combination with 5-Flourouracil/Leucovorin at the 2014 Gastrointestinal Cancers Symposium

PR Newswire January 18, 2014

Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer

PR Newswire January 14, 2014

First Subjects Dosed in Phase 1 Clinical Study of NKTR-171, A New Peripherally-Restricted Sodium Channel Blocker to Treat Neuropathic Pain

PR Newswire January 14, 2014

Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA

PR Newswire January 8, 2014

New Drug Application For Naloxegol Accepted By United States Food And Drug Administration

PR Newswire November 19, 2013